Biohaven Ltd. (NYSE:BHVN - Get Free Report) Director Gregory Bailey bought 48,780 shares of the business's stock in a transaction on Monday, April 22nd. The shares were acquired at an average cost of $41.00 per share, with a total value of $1,999,980.00. Following the purchase, the director now owns 1,574,568 shares of the company's stock, valued at $64,557,288. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Biohaven Price Performance
BHVN opened at $39.60 on Wednesday. Biohaven Ltd. has a 12 month low of $12.35 and a 12 month high of $62.21. The stock has a market capitalization of $3.24 billion, a price-to-earnings ratio of -7.00 and a beta of 1.18. The business has a fifty day moving average price of $51.63 and a 200 day moving average price of $41.70.
Biohaven (NYSE:BHVN - Get Free Report) last released its earnings results on Thursday, February 29th. The company reported ($1.81) EPS for the quarter, missing the consensus estimate of ($1.41) by ($0.40). On average, research analysts anticipate that Biohaven Ltd. will post -5.85 earnings per share for the current year.
Wall Street Analyst Weigh In
Never use this word on your phone (FBI could be watching)
From Paradigm Press | Ad
This report sent a chill down my spine.
Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...
Watch my unredacted video about what I think is coming next right here
Several research firms have issued reports on BHVN. UBS Group raised their target price on Biohaven from $59.00 to $60.00 and gave the stock a "buy" rating in a research note on Tuesday. HC Wainwright raised their target price on Biohaven from $50.00 to $63.00 and gave the stock a "buy" rating in a research note on Monday, March 4th. TD Cowen lifted their price objective on Biohaven from $35.00 to $55.00 and gave the company an "outperform" rating in a research note on Friday, March 1st. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $61.00 price objective on shares of Biohaven in a research note on Tuesday, April 9th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Biohaven in a research note on Thursday, April 18th. Eight investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $52.13.
Get Our Latest Report on Biohaven
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. Thompson Davis & CO. Inc. acquired a new position in Biohaven during the 4th quarter worth $214,000. Prevail Innovative Wealth Advisors LLC acquired a new position in Biohaven during the 4th quarter worth $230,000. Private Advisor Group LLC acquired a new position in Biohaven during the 4th quarter worth $231,000. Capstone Investment Advisors LLC purchased a new stake in Biohaven during the 4th quarter worth about $235,000. Finally, Public Employees Retirement System of Ohio purchased a new stake in Biohaven during the 3rd quarter worth about $236,000. 88.78% of the stock is owned by institutional investors and hedge funds.
Biohaven Company Profile
(
Get Free Report)
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
